Prism’s team of physicians, pharmacists, clinical researchers and scientific writers bring experience from different environments, including the pharmaceutical and diagnostics industries, academia, clinical practice and other agencies.
This important blend allows us to offer complementary skills to bring together high science, clinical research, commercial and regulatory writing projects, alongside the compliance side of our company.
Prism’s expert Senior Management Team provide personable, reliable and responsive support across all our projects. We believe in developing authentic partnerships with our clients so together, we can tackle their healthcare challenges
James moved to the pharmaceutical industry in 1993 after a clinical career in general medicine and anaesthetics. He held a series of global clinical and commercial roles at major pharmaceutical companies prior to founding Prism in 2001. James’s experience spans all phases of clinical research and medical affairs, leading the clinical contribution to many regulatory interactions with the EMA and FDA, as well as launching products. He has published widely across a variety of therapeutic areas and continues to work on client projects.
Jamie joined Prism as a Medical Writer in 2007. Prior to this he completed a PhD in cancer genetics and worked as a post-doctoral research assistant before eventually taking up a lectureship in Oncology at the Advanced Medical and Dental Institute in Penang, Malaysia. Initially based at the head office in Nantwich, Jamie moved to Basel in 2009 to help establish the Prism Swiss office. He now leads the Editorial Team at Prism and is responsible for ensuring the scientific and editorial excellence of all our work.
Claire is an ACA trained accountant and has been Financial Controller at Prism since joining the company in early 2013. Previously she worked in accountancy practice for several years and then for another SME in the service sector prior to a short career break with her young family. Claire is responsible for all aspects of the financial control of Prism’s activities in the UK and Overseas.